OCGN - Ocugen, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Ocugen, Inc.

5 Great Valley Parkway
Suite 160
Malvern, PA 19355
United States

Full Time Employees21

Key Executives

NameTitlePayExercisedYear Born
Dr. Shankar Musunuri M.B.A., Ph.D., MBAFounder, Chairman & CEON/AN/A1964
Dr. Uday B. KompellaFounder & DirectorN/AN/AN/A
Mr. Sanjay S. SubramanianChief Financial OfficerN/AN/A1976
Dr. Rasappa ArumughamChief Scientific OfficerN/AN/A1952
Ms. Kelly A. Beck M.B.A., P.M.P., SPHRVP of Investor Relations & Admin.N/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. Ocugen, Inc. is based in Malvern, Pennsylvania.

Corporate Governance

Ocugen, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.